Brief: Sedana Medical Q3 EBITDA Loss Widens To SEK 25.1 Mln
Oct 25 (Reuters) - Sedana Medical AB (publ) SEDANA.ST :
* Q3 NET SALES FOR QUARTER TOTALLED MSEK 26,5 (28,3)
* Q3 EBITDA TOTALLED MSEK -25,1 (-14,0)
* OUTLOOK: CONSENUS INDICATES MORE NORMALIZED ICU PATIENT
NUMBERS
FROM EARLY 2023
Source text for Eikon: ID:nWkr5syS7F
Further company coverage: SEDANA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln